Cargando…
Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer
BACKGROUND: This was a prospective single-centre, phase I study to document the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended phase II dose for future study of capecitabine in combination with radioembolization. METHODS: Patients with advanced unresectable liver-dom...
Autores principales: | Cohen, S J, Konski, A A, Putnam, S, Ball, D S, Meyer, J E, Yu, J Q, Astsaturov, I, Marlow, C, Dickens, A, Cade, D N, Meropol, N J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102951/ https://www.ncbi.nlm.nih.gov/pubmed/24983373 http://dx.doi.org/10.1038/bjc.2014.344 |
Ejemplares similares
-
Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres
por: Fallahpoor, Maryam, et al.
Publicado: (2017) -
Standardizing SPECT/CT dosimetry following radioembolization with yttrium-90 microspheres
por: Kim, S. Peter, et al.
Publicado: (2021) -
Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023) -
Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres
por: Ebbers, S. C., et al.
Publicado: (2020) -
Yttrium-90 Microsphere Radioembolization for Treatment of Lung Cancer Hepatic Metastases
por: Gaba, Ron C., et al.
Publicado: (2012)